AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17584555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15363008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-run asthma clinics
Number of subjects: 170
Study 15363008 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 170
Study 11530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916
Study 11530028 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg initial dose, titrated to 40 mg if needed)
Number of subjects: 3916
Study 11530028 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916
Study 11530028 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg initial dose, titrated to 40 mg if needed)
Number of subjects: 3916
Study 11530028 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (20 mg initial dose, titrated to 80 mg if needed)
Number of subjects: 3916
Study 9506347 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without chemotherapy
Number of subjects: 99
Study 9506347 — intervention group
Group type: COMPARATOR
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with chemotherapy
Number of subjects: 99
Study 9506347 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated thoracic radiotherapy (SFTRT)
Number of subjects: 99
Study 9506347 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated thoracic radiotherapy (AHTRT)
Number of subjects: 99
Study 7997863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g paracetamol (as propacetamol) intravenously
Number of subjects: 11
Study 7997863 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol (as propacetamol) intravenously
Number of subjects: 11
Study 7997863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g paracetamol (as propacetamol) intravenously
Number of subjects: 11
Study 7997863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 3287974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g single preoperative dose)
Number of subjects: 282
Study 3287974 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 perioperative doses of 2 g)
Number of subjects: 282
Study 29635699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser treatment with a 15 mm diameter beam
Number of subjects: 20
Study 28794290 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning self-care education intervention
Number of subjects: 131
Study 28794290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-learning intervention)
Number of subjects: 131
Study 25273359 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonating arm exerciser (RAE)
Number of subjects: 16
Study 25273359 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 16
Study 23233651 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative epirubicin, cisplatin and fluorouracil (ECF) chemotherapy
Number of subjects: 415
Study 23233651 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive pre-treatment biopsies
Number of subjects: 415
Study 21668343 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Number of subjects: 48
Study 21668343 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF varnish
Number of subjects: 48
Study 21668343 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 48
Study 21668343 — intervention group
Group type: COMPARATOR
Intervention: Placebo NaF varnish
Number of subjects: 48
Study 18310682 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with plate fixation
Number of subjects: 132
Study 18310682 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 132
Study 15973669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (A) 125 mg orally plus Ondansetron (O) 32 mg and Dexamethasone (D) 12 mg on Day 1; A 80 mg and D 8 mg once daily on Days 2-3; D 8 mg on Day 4
Number of subjects: 1043
Study 15973669 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (Ondansetron [O] 32 mg intravenously and Dexamethasone [D] 20 mg orally on Day 1; D 8 mg twice daily on Days 2-4)
Number of subjects: 1043
Study 15973669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen
Number of subjects: 1043
Study 12921622 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEGF
Number of subjects: 37
Study 12921622 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 37
Study 10572606 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B (6-drug weekly chemotherapy regimen for 12 weeks)
Number of subjects: 374
Study 10572606 — intervention group
Group type: COMPARATOR
Intervention: CHOP (standard regimen for 24 weeks)
Number of subjects: 374
Study 10572606 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 374
Study 10572606 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 374
Study 8667538 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (125mg, 250mg, 500mg)
Number of subjects: 692
Study 8667538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 1852297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxybutropate (300 mg three times a day for eight weeks)
Number of subjects: 20
Study 6558291 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-centered health education curriculum
Number of subjects: 234
Study 6558291 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study 30403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Oral Feeding (EOF) group
Number of subjects: 86
Study 30403976 — intervention group
Group type: COMPARATOR
Intervention: Late Oral Feeding (LOF) group
Number of subjects: 86
Study 30170808 — intervention group
Group type: EXPERIMENTAL
Intervention: QTer® and Creatine supplementation
Number of subjects: 108
Study 30170808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 27822013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of clopidogrel/aspirin 75/100 mg
Number of subjects: 60
Study 27822013 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of individual formulations (clopidogrel 75 mg and aspirin 100 mg)
Number of subjects: 60
Study 24381272 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly focused spatial attention
Number of subjects: 0
Study 24381272 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed attention
Number of subjects: 0
Study 21420744 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of psychotropic drugs
Number of subjects: 528
Study 21420744 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of benzodiazepine or related drugs (BZD/BZDRD)
Number of subjects: 528
Study 21420744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not ceasing drug use)
Number of subjects: 528
Study 21041350 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention including patient education and choice of medication, therapy, or both.
Number of subjects: 339
Study 21041350 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 339
Study 17597349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study 17597349 — intervention group
Group type: COMPARATOR
Intervention: Resection without lymphadenectomy
Number of subjects: 0
Study 12890430 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%)
Number of subjects: 172
Study 12890430 — intervention group
Group type: COMPARATOR
Intervention: IGIV-SD (Gamimune N, 10%)
Number of subjects: 172
Study 12890430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IGIV-C and IGIV-SD
Number of subjects: 172
Study 10743445 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg rectally
Number of subjects: 36
Study 10743445 — intervention group
Group type: COMPARATOR
Intervention: placebo suppository
Number of subjects: 36
Study 8729661 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage double-blind, placebo-controlled food challenge (DBPCFC) for immediate reactors
Number of subjects: 69
Study 8729661 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage double-blind, placebo-controlled food challenge (DBPCFC) for delayed reactors
Number of subjects: 69
Study 8729661 — intervention group
Group type: COMPARATOR
Intervention: Skin-prick tests (SPTs)
Number of subjects: 69
Study 8729661 — intervention group
Group type: COMPARATOR
Intervention: Enzyme allergosorbent test (EAST)
Number of subjects: 69
Study 1553891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 200 mg
Number of subjects: 0
Study 1553891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg
Number of subjects: 0
Study 1553891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 400 mg
Number of subjects: 0
Study 1553891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 0
Study 1553891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2581680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intrathecal morphine (Group B)
Number of subjects: 45
Study 2581680 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intrathecal morphine (Group C)
Number of subjects: 45
Study 2581680 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 100 mg (Group A, Control)
Number of subjects: 45
Study 30155645 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr hole cover placement
Number of subjects: 28
Study 30155645 — intervention group
Group type: COMPARATOR
Intervention: No burr hole cover placement (Control)
Number of subjects: 28
Study 26670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (20 mg/kg per day, escalated to maximum tolerated dose)
Number of subjects: 121
Study 26670617 — intervention group
Group type: COMPARATOR
Intervention: Standard transfusions (monthly to maintain 30% sickle haemoglobin or lower)
Number of subjects: 121
Study 26670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 121
Study 26670617 — intervention group
Group type: COMPARATOR
Intervention: Standard transfusions
Number of subjects: 121
Study 26670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 24690513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 16
Study 24690513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22507080 — intervention group
Group type: EXPERIMENTAL
Intervention: FACTS diabetes education programme (six 90‐min monthly sessions attended by parents and adolescents)
Number of subjects: 305
Study 22507080 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical care
Number of subjects: 305
Study 22507080 — intervention group
Group type: EXPERIMENTAL
Intervention: FACTS diabetes education programme
Number of subjects: 305
Study 20409509 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered surgical technique (ligation of lymph vessels, suturing latissimus dorsi to chest wall, fixing skin flap to muscle)
Number of subjects: 201
Study 20409509 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical technique
Number of subjects: 201
Study 18599105 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs rotated to varying extents within a constant square frame
Number of subjects: 0
Study 18599105 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs viewed in interiors and during recognition of previously seen pictures
Number of subjects: 0
Study 16019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (n=15)
Number of subjects: 43
Study 16019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand/face exercises group (n=13)
Number of subjects: 43
Study 16019281 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 43
Study 12240905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Insulin Therapy (IIT)
Number of subjects: 46
Study 12240905 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insulin Therapy (CIT)
Number of subjects: 46
Study 10356917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin delivered via nasal electrophoresis (NE) in combination with standard therapy
Number of subjects: 76
Study 10356917 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 76
Study 8522381 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 474
Study 8522381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg twice daily
Number of subjects: 474
Study 2021151 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol > 6 mmol/liter
Number of subjects: 346
Study 2021151 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol > 3.5 mmol/liter
Number of subjects: 346
Study 2021151 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol > 1.2 mmol/liter
Number of subjects: 346
Study 6460472 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 15
Study 6460472 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 1,000 mg
Number of subjects: 15
Study 30977077 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐S2 (simethicone addition in the evening of the day prior to colonoscopy)
Number of subjects: 234
Study 30977077 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐S1 (simethicone addition in the morning on the day of colonoscopy)
Number of subjects: 234
Study 30977077 — intervention group
Group type: COMPARATOR
Intervention: Control (PEG‐Asc only)
Number of subjects: 234
Study 30977077 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐S2
Number of subjects: 234
Study 30977077 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐S1
Number of subjects: 234
Study 30977077 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 234
Study 28709045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived larger hole (Ebbinghaus illusion with small circles)
Number of subjects: 20
Study 28709045 — intervention group
Group type: COMPARATOR
Intervention: Perceived smaller hole (Ebbinghaus illusion with large circles)
Number of subjects: 20
Study 24983687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175
Study 24983687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFMT)
Number of subjects: 175
Study 23608797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition fluid (30 ml·kg(‐1)·d(‐1))
Number of subjects: 120
Study 23608797 — intervention group
Group type: COMPARATOR
Intervention: Traditional intestinal preparation (fasting, oral antibiotic, cleaning enema)
Number of subjects: 120
Study 23608797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 120
Study 23608797 — intervention group
Group type: COMPARATOR
Intervention: Traditional bowel preparation
Number of subjects: 120
Study 21389858 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of oral flucloxacillin
Number of subjects: 70
Study 21389858 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 70
Study 19637415 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir and ritonavir combination
Number of subjects: 0
Study 19637415 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of lopinavir and ritonavir
Number of subjects: 0
Study 19637415 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0
Study 19637415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 0
Study 17670729 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation A of bi-leaflet prosthesis (hinge mechanism perpendicular to a line drawn between the coronary ostia)
Number of subjects: 21
Study 17670729 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation B of bi-leaflet prosthesis (hinge mechanism parallel to the line between the ostia)
Number of subjects: 21
Study 17670729 — intervention group
Group type: COMPARATOR
Intervention: Bio-prosthesis
Number of subjects: 21
Study 15301651 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple communication about cancer-related issues
Number of subjects: 148
Study 15301651 — intervention group
Group type: COMPARATOR
Intervention: Couple communication about general issues
Number of subjects: 148
Study 11503782 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 0
Study 11503782 — intervention group
Group type: COMPARATOR
Intervention: Abciximab started 24 hours before angioplasty
Number of subjects: 0
Study 9315593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 8397246 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil + Low-salt diet
Number of subjects: 418
Study 8397246 — intervention group
Group type: COMPARATOR
Intervention: Verapamil + High-salt diet
Number of subjects: 418
Study 3526885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin
Number of subjects: 535
Study 3526885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin/amikacin
Number of subjects: 535
Study 3526885 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam/ticarcillin
Number of subjects: 535
Study 3526885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 535
Study 30099555 — intervention group
Group type: EXPERIMENTAL
Intervention: House of Quality for Behavioral Science tool
Number of subjects: 0
Study 29409920 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 13
Study 29409920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27298549 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel staples
Number of subjects: 80
Study 27298549 — intervention group
Group type: COMPARATOR
Intervention: 3‐0 silk sutures
Number of subjects: 80
Study 24906705 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSE protocol (atropine first, 1.0 mg administered 3 min before dobutamine infusion)
Number of subjects: 100
Study 24906705 — intervention group
Group type: COMPARATOR
Intervention: DASE protocol (conventional atropine administration)
Number of subjects: 100
Study 21221681 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence 10% PF™ (OPL)
Number of subjects: 240
Study 21221681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivastyle® 10%™ (VS10%)
Number of subjects: 240
Study 21221681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivadent Paint On Plus™ (PO+)
Number of subjects: 240
Study 21221681 — intervention group
Group type: EXPERIMENTAL
Intervention: Trés White Supreme™ (TWS)
Number of subjects: 240
Study 21221681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 20135933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate sealant (FloraSeal)
Number of subjects: 60
Study 20135933 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (Betadine)
Number of subjects: 60
Study 20135933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Povidone-iodine and cyanoacrylate
Number of subjects: 60
Study 18589451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and higher intravenous amino acid (EHAA) supplementation (2 g x kg(‐1) x d(‐1) advanced by 1 g x kg(‐1) daily to 4 g x kg(‐1) x d(‐1))
Number of subjects: 62
Study 18589451 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous amino acid (SAA) supplementation (starting at 0.5 g x kg(‐1) x d(‐1) increased by 0.5 g x kg(‐1) daily to a maximum of 3 g x kg(‐1) x d(‐1))
Number of subjects: 62
Study 18589451 — intervention group
Group type: EXPERIMENTAL
Intervention: EHAA supplementation
Number of subjects: 62
Study 18589451 — intervention group
Group type: EXPERIMENTAL
Intervention: AA infusion
Number of subjects: 62
Study 16385905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearson correlation coefficient (γ = 1)
Number of subjects: 0
Study 16385905 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendall correlation coefficient (γ = 0)
Number of subjects: 0
Study 16385905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation coefficient (γ = 0.5)
Number of subjects: 0
Study 16385905 — intervention group
Group type: EXPERIMENTAL
Intervention: General class of sample correlation coefficients
Number of subjects: 0
Study 22123096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 9-THC 10 mg QID
Number of subjects: 12
Study 22123096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 9-THC 20 mg QID
Number of subjects: 12
Study 22123096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22123096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 9-THC maintenance
Number of subjects: 12
Study 12019584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 0
Study 12019584 — intervention group
Group type: COMPARATOR
Intervention: No AFO (control condition)
Number of subjects: 0
Study 9850410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 184
Study 9850410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 184
Study 9850410 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 184
Study 9850410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 7505877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD)
Number of subjects: 70
Study 7505877 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD)
Number of subjects: 70
Study 2642499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 16
Study 2642499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 4357222 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 4357222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0